Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)

BACKGROUND: Dacomitinib is a second-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). ARCHER-1050 showed that this agent can improve progression-free survival and overall survival in advanced non-small cell lung cancer patients with sensitive EGFR mutati...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Shi, Chunlei, Gao, Zhiqiang, Zhong, Hua, Xiong, Liwen, Gu, Aiqin, Wang, Weimin, Chu, Tianqing, Zhang, Wei, Wang, Huimin, Zhang, Xueyan, Zhong, Runbo, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933987/
https://www.ncbi.nlm.nih.gov/pubmed/35305596
http://dx.doi.org/10.1186/s12885-022-09409-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933987/
https://www.ncbi.nlm.nih.gov/pubmed/35305596
http://dx.doi.org/10.1186/s12885-022-09409-3

Ejemplares similares